Clinical Trial Update: A Study of ONC201 for Refractory Meningioma [Phase 2]

View source ↗

Summary

A Phase 2 study of ONC201 for refractory meningioma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningioma

Drugs mentioned

• ONC201 (ONC201)

Snippet

Sponsor: University of Nebraska | Conditions: Meningioma, Refractory Meningioma | Phase 2 | Status: WITHDRAWN